Spironolactone

"Spironolactone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)

Descriptor ID	D013148
MeSH Number(s)	D02.540.679 D04.210.500.745.745.855
Concept/Terms	Spironolactone Spironolactone Spirolactone Veroshpiron Verospirone Spiractin Spiractin Spirobeta Spirobeta Spirogamma Spirogamma Spirolang Spirolang Spirono-Isis Spirono-Isis Spirono Isis Spironone Spironone Spirospare Spirospare Aldactone Aldactone Verospiron Verospiron Aldactone A Aldactone A Aquareduct Aquareduct Duraspiron Duraspiron Espironolactona Alter Espironolactona Alter Espironolactona Mundogen Espironolactona Mundogen Flumach Flumach Frumikal Frumikal Jenaspiron Jenaspiron Novo-Spiroton Novo-Spiroton Novo Spiroton NovoSpiroton Practon Practon SC-9420 SC-9420 SC 9420 SC9420 Spiro L.U.T. Spiro L.U.T. Spiro Von Ct Spiro Von Ct Ct, Spiro Von Von Ct, Spiro

Below are MeSH descriptors whose meaning is more general than "Spironolactone".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Lactones [D02.540]
Spironolactone [D02.540.679]
Polycyclic Compounds [D04]
Fused-Ring Compounds [D04.210]
Steroids [D04.210.500]
Pregnanes [D04.210.500.745]
Pregnenes [D04.210.500.745.745]
Spironolactone [D04.210.500.745.745.855]

Below are MeSH descriptors whose meaning is related to "Spironolactone".

Below are MeSH descriptors whose meaning is more specific than "Spironolactone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Spironolactone" by people in this website by year, and whether "Spironolactone" was a major or minor topic of these publications.

Bar chart showing 11 publications over 8 distinct years, with a maximum of 2 publications in 2011 and 2014 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	1	0	1
2005	0	1	1
2010	0	1	1
2011	2	0	2
2014	1	1	2
2015	1	0	1
2019	0	2	2
2020	1	0	1

Below are the most recent publications written about "Spironolactone" by people in Profiles.

Cunningham JW, Vaduganathan M, Claggett BL, John JE, Desai AS, Lewis EF, Zile MR, Carson P, Jhund PS, Kober L, Pitt B, Shah SJ, Swedberg K, Anand IS, Yusuf S, McMurray JJV, Pfeffer MA, Solomon SD. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. JACC Heart Fail. 2020 08; 8(8):618-626.

View in: PubMed
Matheson E, Bain J. Hirsutism in Women. Am Fam Physician. 2019 08 01; 100(3):168-175.

View in: PubMed
Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2019 05; 7(5):418-427.

View in: PubMed
Chadwick JA, Hauck JS, Lowe J, Shaw JJ, Guttridge DC, Gomez-Sanchez CE, Gomez-Sanchez EP, Rafael-Fortney JA. Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target. FASEB J. 2015 Nov; 29(11):4544-54.

View in: PubMed
Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.

View in: PubMed
Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014 May; 34(3):273-84.

View in: PubMed
Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.

View in: PubMed
Rigsby CS, Ergul A, Portik Dobos V, Pollock DM, Dorrance AM. Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens. 2011 Jun; 24(6):708-15.

View in: PubMed
Egan BM. Overnight rostral fluid shift and obstructive sleep apnea in treatment resistant hypertension: connecting the dots clarifies the picture. Hypertension. 2010 Dec; 56(6):1040-1.

View in: PubMed
Mulholland PJ, Self RL, Harris BR, Little HJ, Littleton JM, Prendergast MA. Corticosterone increases damage and cytosolic calcium accumulation associated with ethanol withdrawal in rat hippocampal slice cultures. Alcohol Clin Exp Res. 2005 May; 29(5):871-81.

View in: PubMed

People

Explore

Similar Concepts

Top Journals